Preventing genetic defects part 2

Preventing genetic defects part 2

NGS based PGS/PGD tests developed by the Invicta’s research team use semiconductor technology, in which chemical reactions are recorded directly in the form of an electrical impulse, without any additional intermediate steps. Reads are based directly on the genetic information, and not associated with changes in markers or tags dependent on color reactions. As a result, they have confidence in the result and access to greater amounts of data. Previusly this solution helped in diagnosing adults – Invicta’s scientists use them now to study the DNA of embryos (so called. preimplantation genetic diagnosis or PGD).

Since 2005, as a first clinic in Poland, Invicta has been performing genetic testing of embryos. We have gained essential experience and knowledge, and carried out our own research projects. Now we can use that to create something new, an even more accurate method giving us unprecedented possibilities. For many of our patients genetic diagnosis of embryos is the only chance for having a healthy child – emphasizes prof. Łukaszuk.

Over the past ten years specialists from Invicta performed over 8000 PGS/PGD tests. Currently they routinely carry out PGS NGS for aneuploidy, i.e., the abnormal number of chromosomes. This type of abnormalities can cause severe fetal defects such as Down, Turner, Edwards, Patau or Klinefelter syndromes. It is also possible to simultaneously test the embryo for a specific monogenic disease (e.g., CF).

INVICTA-Genetics
INVICTA-Genetics
INVICTA Genetic Laboratory has been performing genetic screening of embryos since 2005. Our team of world-class experts and scientists has been developing the innovative methods of preimplantation genetic diagnosis (PGD) for over 13 years.